La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Novozymes Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Novozymes ha un patrimonio netto totale di DKK14.4B e un debito totale di DKK7.4B, che porta il suo rapporto debito/patrimonio netto a 51.6%. Le sue attività totali e le sue passività totali sono rispettivamente DKK28.4B e DKK14.0B. L'EBIT di Novozymes è DKK4.5B rendendo il suo rapporto di copertura degli interessi 53.8. Ha liquidità e investimenti a breve termine pari a DKK1.1B.

Informazioni chiave

51.6%

Rapporto debito/patrimonio netto

DKK 7.41b

Debito

Indice di copertura degli interessi	53.8x
Contanti	DKK 1.12b
Patrimonio netto	DKK 14.35b
Totale passività	DKK 14.04b
Totale attività	DKK 28.39b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( DKK9.5B ) di NSIS N superano le sue passività a breve termine ( DKK7.3B ).

Passività a lungo termine: Le attività a breve termine di NSIS N ( DKK9.5B ) superano le sue passività a lungo termine ( DKK6.8B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 43.9% ) di NSIS N è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di NSIS N è aumentato da 28.5% a 51.6% negli ultimi 5 anni.

Copertura del debito: Il debito di NSIS N è ben coperto dal flusso di cassa operativo ( 56% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di NSIS N sono ben coperti dall'EBIT ( 53.8 x copertura).

Novozymes Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Less than half of directors are independent

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Less than half of directors are independent

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Less than half of directors are independent

Upcoming dividend of kr.5.50 per share

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Revenue Guidance for 2022

Less than half of directors are independent

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane